Looking forward in the treatment of deep-vein thrombosis (Q34306094)

1 August 2017

1 reference

title

Looking forward in the treatment of deep-vein thrombosis (English)

1 reference

1 August 2017

1 reference

Turpie AG

1

1 reference

1 August 2017

publication date

1 April 2001

1 reference

1 August 2017

published in

Seminars in Hematology

1 reference

1 August 2017

volume

38

1 reference

1 August 2017

issue

2 Suppl 5

1 reference

1 August 2017

page(s)

49-57

1 reference

Current issues in management of thromboses

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

1 reference

7 January 2021

Antithrombotic therapy for venous thromboembolic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Antithrombotic therapy for venous thromboembolic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Antithrombotic therapy for venous thromboembolic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Recurrent pulmonary embolism. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Economic evaluation of the use of nadroparin in the treatment of deep-vein thrombosis in Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Outpatient management of deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Risk of fatal pulmonary embolism in patients with treated venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

The Long-Term Clinical Course of Acute Deep Venous Thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990098-8

7 January 2021

10.1016/S0037-1963(01)90098-8

Identifiers

DOI

1 reference

1 August 2017

1 reference